6-May-2025 6:05 AM CST - Business Wire Ionis to host 2025 virtual Annual Meeting of Stockholders Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. 5:15 p.m. ET (2:00 p.m. 2:15 p.m. PT) Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting we
30-Apr-2025 6:00 AM CST - Business Wire Ionis reports first quarter 2025 financial results Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the Company) today reported financial results for the first quarter ended March 31, 2025. With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis new chapter as a fully integrated, commercial-stage biotechnology company is well underway, said Brett P. Monia, Ph.D., chief executive officer, Ionis. We l
16-Apr-2025 6:05 AM CST - Business Wire Ionis to hold first quarter 2025 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better future
3-Apr-2025 6:05 AM CST - Business Wire Ionis to host expert panel discussion on sHTG Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet medical needs associated with severe hypertriglyceridemia (sHTG). Key thought leaders in lipidology, cardiology and endocrinology will join Sam Tsimikas, M.D., senior vice president, global cardiovascular development, Ionis, for a live discussion followed by a brief Q&A se
31-Mar-2025 6:05 AM CST - Business Wire Ionis to present at upcoming investor conferences Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 Bank of America 2025 Health Care Conference on Wednesday, May 14, 2025 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025 A live webcast of these presentations can be accessed on the Investors & Media secti
25-Feb-2025 6:05 AM CST - Business Wire Ionis to present at upcoming investor conferences Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 U
19-Feb-2025 6:00 AM CST - Business Wire Ionis reports fourth quarter and full year 2024 financial results Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the Company) today reported financial results for the fourth quarter and full year ended December 31, 2024. With the recent launch of our first independent medicine, TRYNGOLZA for familial chylomicronemia syndrome, Ionis has begun a new chapter as a fully integrated commercial-stage biotechnology company, said Brett P. Monia, Ph.D., chief executive officer, Ionis. Over the next three years, we expect three more
5-Feb-2025 6:05 AM CST - Business Wire Ionis to hold fourth quarter and full year 2024 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that b
6-May-2025 6:05 AM CST - Business Wire Ionis to host 2025 virtual Annual Meeting of Stockholders Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. 5:15 p.m. ET (2:00 p.m. 2:15 p.m. PT) Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting we
30-Apr-2025 6:00 AM CST - Business Wire Ionis reports first quarter 2025 financial results Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the Company) today reported financial results for the first quarter ended March 31, 2025. With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis new chapter as a fully integrated, commercial-stage biotechnology company is well underway, said Brett P. Monia, Ph.D., chief executive officer, Ionis. We l
16-Apr-2025 6:05 AM CST - Business Wire Ionis to hold first quarter 2025 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better future
3-Apr-2025 6:05 AM CST - Business Wire Ionis to host expert panel discussion on sHTG Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet medical needs associated with severe hypertriglyceridemia (sHTG). Key thought leaders in lipidology, cardiology and endocrinology will join Sam Tsimikas, M.D., senior vice president, global cardiovascular development, Ionis, for a live discussion followed by a brief Q&A se
31-Mar-2025 6:05 AM CST - Business Wire Ionis to present at upcoming investor conferences Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 Bank of America 2025 Health Care Conference on Wednesday, May 14, 2025 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025 A live webcast of these presentations can be accessed on the Investors & Media secti
25-Feb-2025 6:05 AM CST - Business Wire Ionis to present at upcoming investor conferences Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 U
19-Feb-2025 6:00 AM CST - Business Wire Ionis reports fourth quarter and full year 2024 financial results Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the Company) today reported financial results for the fourth quarter and full year ended December 31, 2024. With the recent launch of our first independent medicine, TRYNGOLZA for familial chylomicronemia syndrome, Ionis has begun a new chapter as a fully integrated commercial-stage biotechnology company, said Brett P. Monia, Ph.D., chief executive officer, Ionis. Over the next three years, we expect three more
5-Feb-2025 6:05 AM CST - Business Wire Ionis to hold fourth quarter and full year 2024 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that b
